ong-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel
Phase 4
- Conditions
- Multiple Myelomaplasma cell myeloma10040778
- Registration Number
- NL-OMON53393
- Lead Sponsor
- Janssen-Cilag International NV
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 6
Inclusion Criteria
1. Subjects who have received at least one dose of cilta-cel in a
Company-sponsored clinical study.
2. Subjects who have provided informed consent for Study MMY4002.
Exclusion Criteria
No exclusion criteria are applicable in this study.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method